Entera Bio (STU:5DT) Short-Term Debt: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5DT Entera Bio Ltd STU:5DT
37 GF Score
Price €2.46
GF Value €0.21
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Entera Bio Short-Term Debt?

Entera Bio STU:5DT 37 Short-Term Debt is €0.00 Mil as of Jun. 2026. GuruFocus rates STU:5DT with a GF Score™ of 37/100 and a GF Value™ of €0.21 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Entera Bio's Short-Term Debt for the quarter that ended in Jun. 2026 was €0.00 Mil.

Entera Bio Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Entera Bio Short-Term Debt Related Terms

Entera Bio Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Entera Bio's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio Short-Term Debt Chart

Entera Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entera Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:5DT
37GF Score
Entera Bio Ltd STU:5DT
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €0.00 Mil mean?
Entera Bio (STU:5DT) has a Short-Term Debt of €0.00 Mil as of Jun. 2026.
Is Entera Bio's Short-Term Debt too high?
Entera Bio's current Short-Term Debt is €0.00 Mil. Overall, Entera Bio has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's Short-Term Debt compare to ICCC and BDTX?
Entera Bio's Short-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Entera Bio's current Short-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Based on GuruFocus' analysis, Entera Bio (STU:5DT) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.21, compared to a current price of €2.46 — trading 1071.4% above its estimated fair value. The current Short-Term Debt is €0.00 Mil. Entera Bio's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Entera Bio (STU:5DT), the current Short-Term Debt is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Entera Bio (STU:5DT) Overvalued in 2026?

Based on GuruFocus' analysis, Entera Bio stock appears to be overvalued. The current stock price of €2.46 is trading 1071.4% above its estimated GF Value™ of €0.21. GuruFocus considers Entera Bio to be Significantly Overvalued.

Key valuation signals for STU:5DT:

  • Short-Term Debt: €0.00 Mil
  • GF Value™: €0.21 vs. price of €2.46 (1071.4% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the STU:5DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entera Bio Business Description

Other Exchanges ENTX:USA
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
37GF Score

Get the complete analysis for STU:5DT

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.46
Price
€0.21
GF Value